Lindbrook Capital, LLC Athira Pharma, Inc. Transaction History

Lindbrook Capital, LLC

  • $1.09 Billion
  • Q4 2024

A detailed history of Lindbrook Capital, LLC transactions in Athira Pharma, Inc. stock. As of the latest transaction made, Lindbrook Capital, LLC holds 8,920 shares of ATHA stock, worth $4,192. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8,920
Previous 8,920 -0.0%
Holding current value
$4,192
Previous $4,000 25.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024
SELL
$0.42 - $3.43 $1,603 - $13,095
-3,818 Reduced 29.97%
8,920 $4,000
Q1 2024

Apr 25, 2024
BUY
$2.24 - $4.15 $6,720 - $12,450
3,000 Added 30.81%
12,738 $34,000
Q3 2023

Oct 25, 2023
SELL
$1.9 - $3.16 $3,171 - $5,274
-1,669 Reduced 14.63%
9,738 $19,000
Q4 2022

Jan 24, 2023
SELL
$2.76 - $3.71 $15,215 - $20,453
-5,513 Reduced 32.58%
11,407 $0
Q3 2022

Nov 10, 2022
SELL
$2.93 - $3.96 $19,045 - $25,740
-6,500 Reduced 27.75%
16,920 $50,000
Q2 2022

Aug 01, 2022
SELL
$2.74 - $13.43 $2,063 - $10,112
-753 Reduced 3.12%
23,420 $71,000
Q1 2022

Apr 21, 2022
BUY
$8.96 - $13.51 $8,538 - $12,875
953 Added 4.1%
24,173 $326,000
Q4 2021

Jan 18, 2022
BUY
$9.17 - $16.39 $75,093 - $134,217
8,189 Added 54.48%
23,220 $303,000
Q3 2021

Nov 05, 2021
SELL
$9.15 - $11.09 $229,738 - $278,447
-25,108 Reduced 62.55%
15,031 $141,000
Q2 2021

Jul 27, 2021
BUY
$10.24 - $20.87 $155,770 - $317,474
15,212 Added 61.03%
40,139 $411,000
Q1 2021

Apr 28, 2021
SELL
$16.9 - $29.77 $35,490 - $62,517
-2,100 Reduced 7.77%
24,927 $459,000
Q4 2020

Jan 27, 2021
BUY
$16.48 - $34.3 $188,728 - $392,803
11,452 Added 73.53%
27,027 $926,000
Q3 2020

Nov 03, 2020
BUY
$16.02 - $18.46 $249,511 - $287,514
15,575 New
15,575 $288,000

Others Institutions Holding ATHA

# of Institutions
64
Shares Held
19M
Call Options Held
23.6K
Put Options Held
68K
View Full List

About Athira Pharma, Inc.

ATHA Quotes by TradingView
  • Ticker ATHA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,817,700
  • Market Cap $17.8M
  • Description
  • Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...
More about ATHA
Track This Portfolio

Track Lindbrook Capital, LLC Portfolio

Follow Lindbrook Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lindbrook Capital, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email